Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

S. Honig, Lawrence; Vellas, Bruno; Woodward, Mark; Boada, Merçé; Bullock, Roger; Borrie, Michael; Häger, Klaus; Andreasen, Niels; Scarpini, Elio; Liu‐Seifert, Hong; Case, Michael; A. Dean, Robert; Marie Hake, Ann; Sundell, Karen; Poole Hoffmann, Vicki; Carlson, Christopher; Khanna, Rashna; A. Mintun, Mark; B. DeMattos, Ronald; J. Selzler, Katherine; Siemers, Eric

doi:10.1056/nejmoa1705971

Public

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

Published in New England Journal of Medicine • Jan 25, 2018

Authors:

Lawrence S. Honig

Bruno Vellas

Mark Woodward

Abstract

BACKGROUND: Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposi...

Subject

Placebo

Dementia

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!